Viewing Study NCT06206720



Ignite Creation Date: 2024-05-06 @ 7:58 PM
Last Modification Date: 2024-10-26 @ 3:18 PM
Study NCT ID: NCT06206720
Status: RECRUITING
Last Update Posted: 2024-07-09
First Post: 2023-12-28

Brief Title: A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
Sponsor: Vigonvita Life Sciences
Organization: Vigonvita Life Sciences

Study Overview

Official Title: A Randomized Double-blind Placebo-controlled Phase IIIII Clinical Trial to Evaluate the Safety and Efficacy of Deuremidevir Hydrobromide for Suspension in Hospitalized Infants Infected With Respiratory Syncytial Virus
Status: RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the safety efficacy pharmacokinetic PK characteristics and antiviral activity of different doses of Deuterium Hydrobromide for suspension in the treatment of respiratory syncytial virus infection in infants
Detailed Description: This trial is a randomized double-blind placebo-controlled dose-ascending trial and the subjects are infants infected with RSV from 1 to 24 months

It is estimated that 60 subjects will be included and divided into low-dose group 15 mgkgBID middle-dose group 20 mgkgBID and high-dose group 20 mgkgTID with 20 cases in each group and they will be randomly assigned to the experimental drug group and the placebo group according to the ratio of 3 1

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None